---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-006611"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-09-22T23:59:59+00:00"
generated_at: "2026-06-10T09:36:16.072842+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma gets 180-day Nasdaq bid-price compliance extension to March 18, 2024

## Summary
- Received 180-day Nasdaq extension until March 18, 2024 to meet $1.00 min bid price.
- Company meets all other continued listing requirements except bid price.
- Intends to cure deficiency, potentially via reverse stock split if necessary.
- No immediate effect on listing or trading; common stock continues on Nasdaq under 'SBFM'.
- Compliance can be regained if closing bid price ≥$1.00 for 10 consecutive business days before deadline.

## SEC filing metadata
- accession: 0001683168-23-006611
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-09-22T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823006611/0001683168-23-006611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823006611/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-006611
- JSON: https://secwatch.observer/filing/0001683168-23-006611.json
- Plain text: https://secwatch.observer/filing/0001683168-23-006611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.